LivaNova PLC (NASDAQ:LIVN) Exceeds Market Expectations with Strong Q3 Financial Performance

Font: Financial Modeling Prep  • Nov 05, 2025

• LivaNova PLC's earnings per share (EPS) for Q3 reached $1.11, surpassing the Zacks Consensus Estimate.
• The company reported a revenue of $357.8 million, indicating a 12.5% growth from the previous year.
• Despite challenges, LivaNova's debt-to-equity ratio of 0.42 and a current ratio of 1.29 reflect a balanced financial health.

LivaNova PLC (NASDAQ:LIVN) is a prominent player in the medical technology sector, specializing in innovative medical devices. The company operates within the Zacks Medical - Instruments industry, competing with other major firms in the field. On November 5, 2025, LivaNova reported its third-quarter earnings, showcasing strong financial performance that exceeded market expectations.

LivaNova's earnings per share (EPS) for the quarter reached $1.11, surpassing the Zacks Consensus Estimate of $0.91. This represents a significant improvement from the $0.90 per share reported in the same quarter last year. The earnings surprise for this quarter stands at nearly 22%, highlighting the company's ability to outperform market predictions consistently.

In terms of revenue, LivaNova generated $357.8 million, exceeding the Zacks Consensus Estimate by almost 4%. This marks a notable increase from the $318.1 million reported for the same period last year, reflecting a 12.5% growth on a reported and organic basis. The company's consistent performance in surpassing revenue estimates underscores its strong market position.

The price-to-sales ratio of 2.22 suggests that investors are willing to pay $2.22 for every dollar of the company's sales. LivaNova maintains a moderate debt level with a debt-to-equity ratio of 0.42, indicating a balanced approach to financing. The current ratio of 1.29 suggests that the company has a reasonable level of liquidity to cover its short-term liabilities. Despite the challenges, LivaNova's strong revenue growth and consistent earnings surprises position it well in the competitive medical technology market.